7.(amended) The solid preparation for oral administration according to claim[s] 4[, 5 or 6] wherein the disintegrator contained in the core containing the gene-related drug is in the range of 2-15 wt.%.

8.(amended) The solid preparation for oral administration according to [any of] claim[s] 4[-7] wherein the disintegrator is mixed for the production in the ratio of 1:0.05-1:10 against the content of the gene-related drug.

A2

9.(amended) The solid preparation for oral administration according to [any of] claim[s] 3[-8] wherein the excipient contained in the core containing the gene-related drug is in the range of 0.1-15 wt.%.

10.(amended) The solid preparation for oral administration according to [any of] claim[s] 1[-9] wherein the gene-related drug contained in the core containing the gene-related drug is in the range of 0.1-50 wt.%.

11.(amended) The solid preparation for oral administration according to [any of] claim[s] 2[-10] wherein the binder contained in the core containing the gene-related drug is in the range of 5-40 wt.%.

12.(amended) The solid preparation for oral administration according to [any of] claim[s] 4[-11] wherein the disintegrators are crospovidone, alpha starch, sodium carboxymethyl starch, carmellose, calcium carmellose, sodium carmellose, agar powder, sodium croscarmellose, crystalline cellulose, low substituted hydroxypropyl cellulose, starch, dextrin, hydroxyethylmethyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, macrogol and mannitol.

13.(amended) The solid preparation for oral administration according to [any of] claim[s] 4[-12] wherein the saccharides are monosaccharides and disaccharides such as lactose, fructose, sucrose, glucose xylitol, maltose, mannitol and sorbitol, or polysaccharides and derivatives

thereof such as cellulose, crystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, ethyl cellulose, starch, dextrin, dextran, pectin and pullulan.

14.(amended) The solid preparation for oral administration according to [any of] claim[s] 3[-13] wherein the excipients are light anhydrous silicic acid, ethyl cellulose, carmellose, agar, magnesium aluminosilicate, calcium silicate, magnesium silicate, cyclodextrin, starch, synthetic aluminum silicate, synthetic hydrotalcite, titanium oxide, zinc oxide, magnesium oxide, alumina magnesium hydroxide, magnesium stearate, calcium stearate, aluminum silicate, talc, crystalline cellulose and lactose.

A2

15.(amended) The solid preparation for oral administration according to [any of] claim[s] [3-13] 1 wherein the gene-related drugs are DNA or RNA, or modified compounds thereof, or compounds thereof conjugated or bound to a carrier.

16.(amended) The solid preparation for oral administration according to [any of] claim[s] 2[-15] wherein the binders are crystalline cellulose, gum arabic, sodium alginate, ethyl cellulose, agar, carboxyvinyl polymer, carmellose, gelatin, low substituted hydroxypropyl cellulose, starch, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, pectin, polyvinylpyrrolidone, macrogol and methyl cellulose.

18.(amended) The solid preparation for oral administration according to [any of] claim[s] 1[-14 and 16] wherein the gene-related drugs are one or more drugs selected from the group comprising a nucleic acid, oligonucleotide, antisense, triple helix forming oligonucleotide (TFO), ribozyme, decoy, plasmid, cosmid, P1 phage, YAC (yeast artificial chromosome), chromosome, aptamer and phage.